Priscila Pereira Sena

Priscila Pereira Sena

Auto-generated profile, based on publicly available information

Priscila Pereira Sena

Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2019 in BioMed Research International
Verified
Journal Article
Open access
Jonasz Jeremiasz WeberJonasz Jeremiasz Weber
Jonasz Jeremiasz Weber
PSPriscila Pereira Sena
Priscila Pereira Sena
ESElisabeth Singer
Elisabeth Singer
HNHuu Phuc Nguyen
Huu Phuc Nguyen
Proteolytic machineries execute vital cellular functions and their disturbances are implicated in diverse medical conditions, including neurodegenerative diseases. Interestingly, calpains, a class of Ca2+-dependent regulatory proteases, can modulate the degradational system of autophagy by cleaving proteins involved in this pathway. Moreover, both machineries are common players in many molecular pathomechanisms and have been targeted individually or together, as a therapeutic strategy in experimental setups. In this review, we briefly introduce calpains and autophagy, with their roles in health and disease, and focus on their direct pathologically relevant interplay in neurodegeneration and beyond. The modulation of calpain activity may comprise a promising treatment approach to attenuate the deregulation of these two essential mechanisms.

1 August 2024 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
Jonasz Jeremiasz WeberJonasz Jeremiasz Weber
Jonasz Jeremiasz Weber
LCLeah Czisch
Leah Czisch
PSPriscila Pereira Sena
Priscila Pereira Sena
FFFlorian Fath
Florian Fath
CHChrisovalantou Huridou
Chrisovalantou Huridou
TSThorsten Schmidt
Thorsten Schmidt
Machado–Joseph disease (MJD) is an autosomal dominant neurodegenerative spinocerebellar ataxia caused by a polyglutamine-coding CAG repeat expansion in the ATXN3 gene. While the CAG length correlates negatively with the age at onset, it accounts for approximately 50% of its variability only. Despite larger efforts in identifying contributing genetic factors, candidate genes with a robust and plausible impact on the molecular pathogenesis of MJD are scarce. Therefore, we analysed missense single nucleotide polymorphism variants in the PRKN gene encoding the Parkinson's disease-associated E3 ubiquitin ligase parkin, which is a well-described interaction partner of the MJD protein ataxin-3, a deubiquitinase. By performing a correlation analysis in the to-date largest MJD cohort of more than 900 individuals, we identified the V380L variant as a relevant factor, decreasing the age at onset by 3 years in homozygous carriers. Functional analysis in an MJD cell model demonstrated that parkin V380L did not modulate soluble or aggregate levels of ataxin-3 but reduced the interaction of the two proteins. Moreover, the presence of parkin V380L interfered with the execution of mitophagy—the autophagic removal of surplus or damaged mitochondria—thereby compromising cell viability. In summary, we identified the V380L variant in parkin as a genetic modifier of MJD, with negative repercussions on its molecular pathogenesis and disease age at onset.

28 April 2022 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
Jonasz Jeremiasz WeberJonasz Jeremiasz Weber
Jonasz Jeremiasz Weber
SAStefanie Cari Anger
Stefanie Cari Anger
PSPriscila Pereira Sena
Priscila Pereira Sena
RERana Dilara Incebacak Eltemur
Rana Dilara Incebacak Eltemur
CHChrisovalantou Huridou
Chrisovalantou Huridou
Huu Phuc NguyenHuu Phuc Nguyen
Huu Phuc Nguyen
Spinocerebellar ataxia type 17 (SCA17) is a neurodegenerative disease caused by a polyglutamine-encoding trinucleotide repeat expansion in the gene of transcription factor TATA box-binding protein (TBP). While its underlying pathomechanism is elusive, polyglutamine-expanded TBP fragments of unknown origin mediate the mutant protein’s toxicity. Calcium-dependent calpain proteases are protagonists in neurodegenerative disorders. Here, we demonstrate that calpains cleave TBP, and emerging C-terminal fragments mislocalize to the cytoplasm. SCA17 cell and rat models exhibited calpain overactivation, leading to excessive fragmentation and depletion of neuronal proteins in vivo. Transcriptome analysis of SCA17 cells revealed synaptogenesis and calcium signaling perturbations, indicating the potential cause of elevated calpain activity. Pharmacological or genetic calpain inhibition reduced TBP cleavage and aggregation, consequently improving cell viability. Our work underlines the general significance of calpains and their activating pathways in neurodegenerative disorders and presents these proteases as novel players in the molecular pathogenesis of SCA17.

16 November 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PSPriscila Pereira Sena
Priscila Pereira Sena
Jonasz Jeremiasz WeberJonasz Jeremiasz Weber
Jonasz Jeremiasz Weber
MWMaxinne Watchon
Maxinne Watchon
KRKatherine Robinson
Katherine Robinson
Zinah WassoufZinah Wassouf
Zinah Wassouf
TSThorsten Schmidt
Thorsten Schmidt
Significance: Machado–Joseph disease (MJD) is an incurable neurodegenerative disorder caused by a mutation in the ataxin-3 protein, which becomes toxic and induces cerebellar degeneration and motor impairments. Disturbances in the protein modification O -GlcNAcylation, catalyzed by the enzyme O -GlcNAc transferase (OGT), have been linked to neurodegeneration, but its potential involvement in MJD remains elusive. By analyzing MJD cells and animal models, we demonstrate altered levels of OGT in MJD, further identifying this enzyme as a substrate of ataxin-3. Targeting OGT reduced ataxin-3 toxicity, improving the motor phenotype of an MJD animal model. Our results unveiled a physiological interplay between ataxin-3 and OGT, highlighting OGT as a potential therapeutic target in this deadly condition.

19 March 2021 in Molecular Brain
Verified
Journal Article
Open access
PDF file
ASAnna S. Sowa
Anna S. Sowa
TPTaissia G. Popova
Taissia G. Popova
THTina Harmuth
Tina Harmuth
Jonasz Jeremiasz WeberJonasz Jeremiasz Weber
Jonasz Jeremiasz Weber
PSPriscila Pereira Sena
Priscila Pereira Sena
TSThorsten Schmidt
Thorsten Schmidt
Spinocerebellar ataxia type 3 (SCA3) is a rare neurodegenerative disorder resulting from an aberrant expansion of a polyglutamine stretch in the ataxin-3 protein and subsequent neuronal death. The underlying intracellular signaling pathways are currently unknown. We applied the Reverse-phase Protein MicroArray (RPMA) technology to assess the levels of 50 signaling proteins (in phosphorylated and total forms) using three in vitro and in vivo models expressing expanded ataxin-3: (i) human embryonic kidney (HEK293T) cells stably transfected with human ataxin-3 constructs, (ii) mouse embryonic fibroblasts (MEF) from SCA3 transgenic mice, and (iii) whole brains from SCA3 transgenic mice. All three models demonstrated a high degree of similarity sharing a subset of phosphorylated proteins involved in the PI3K/AKT/GSK3/mTOR pathway. Expanded ataxin-3 strongly interfered (by stimulation or suppression) with normal ataxin-3 signaling consistent with the pathogenic role of the polyglutamine expansion. In comparison with normal ataxin-3, expanded ataxin-3 caused a pro-survival stimulation of the ERK pathway along with reduced pro-apoptotic and transcriptional responses.

14 February 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
BMBenita Menden
Benita Menden
RERana D. Incebacak Eltemur
Rana D. Incebacak Eltemur
GDGerman Demidov
German Demidov
MSMarc Sturm
Marc Sturm
JPJoohyun Park
Joohyun Park
THTobias Haack
Tobias Haack
Most patients with a rare movement disorder (MD) do not receive a molecular diagnosis, and the underlying genetic variants and mediating genes remain elusive. Here, we evaluate the diagnostic accuracy of conventional and next-generation sequencing-based genetic testing strategies in a cohort of 2,811 individuals with ataxia, spastic paraplegia and dystonia. Exome sequencing establishes genetic diagnoses in 19.3% of cases, and specificity of phenotypic features and age at testing are positive predictors. Genome analysis ‘beyond the exome’ increases the diagnostic yield by 7.5%, mostly due to the improved detection of structural variants and repeat expansions. Unsolved cases are included in the Solve-RD cohort and subjected to gene-burden analysis, providing evidence for loss-of-function variants in X-chromosomal CD99L2 causing spastic ataxia. Cellular studies show that the transmembrane protein CD99L2 occurs mainly in a ubiquitinated form and serves as an activating interactor of the calcium-dependent protease CAPN1. Ablation of cytoplasmic or extracellular domains of CD99L2 leads to its intracellular mislocalization and abrogation of its interplay with CAPN1. Transcriptome analysis in CD99L2 patient-derived fibroblasts reveals synaptic function-specific disturbances. Impaired CAPN1 activation and dysregulation of downstream neuronal pathways constitute the likely molecular cause for neurodegeneration.